Zuklopentiksol dekanoattan paliperidon palmitata geçiş sonrasında tardiv diskinezide düzelme: Bir olgu sunumu

Zuklopentiksol dekanoattan paliperidon palmitata geçiş sonrasında tardiv diskinezide düzelme: Bir olgu sunumuUzun etkili enjektabl antipsikotikler şizofrenide etkili bir tedavi seçeneğidir ve ilacı bırakma potansiyelinin yüksek olduğu hastalarda tedavi uyumunu artırmaktadır. Tardiv diskinezi, uzun süre antipsikotik kullanımı sonrasında sorun olabilen tedavi edilmesi zor bir hareket bozukluğudur. Uzun etkili formları olan atipik antipsikotikler akut ekstrapiramidal yan etkiler için daha güvenli bir seçenek olmalarına karşın, tardiv diskinezideki etkileri net değildir. Güçlü dopamin (D2) reseptör antagonisti özelliği bulunan uzun etkili enjektabl bir antipsikotik olan zuklopentiksol dekanoatın uzun süre kullanımı sonrası gelişen, perioral ve dil bölgesinde tardiv diskinezisi olan bir olguyu bildirmekteyiz. Yirmi beş yıllık şizofreni öyküsü bulunan, 45 yaşındaki beyaz erkek hasta, tardiv diskinezi fark edildiği zaman olanzapin ve zuklopentiksol dekanoat kullanmaktaydı. Son 6 ayda zuklopentiksol dekanoatla beraber çeşitli aralıklarla klorpromazin, haloperidol, olanzapin ve ketiapin kullanımı da olmuştu. Orofarinjiyal diskineziyi ölçmekte Anormal Hareket Bozuklukları Ölçeği kullanıldı. Geçmişte oral tedavi ile tedavi uyumsuzluğu öyküsü bulunduğundan uzun etkili enjektabl antipsikotik kullanımına devam etmeyi planladık. İkinci kuşak uzun etkili enjektabl antipsikotiklerden olan ve dopamin (D2), serotonin (5HT-2), noradrenalin (NE-alfa2) reseptörlerinde antagonist etkisi olan paliperidon palmitat olarak antipsikotik tedavisi değiştirildikten sonra, tardiv diskinezide düzelme gözlemledik

Improvement of Tardive Dyskinesia after Switching from Zuclopenthixol Decanoate to Paliperidone Palmitate: a Case Report

Improvement of tardive dyskinesia after switching from zuclopenthixol decanoate to paliperidone palmitate: a case report Long-acting injectable (LAI) antipsychotics are an effective option in schizophrenia that increase treatment adherence in potentially non-compliant patients. Tardive dyskinesia is a potentially treatment-resistant movement disorder that can be a problem after long-term antipsychotic use. Atypical antipsychotics with long-acting formulations offer a safer option for acute extrapyramidal side effects, but their effect in tardive dyskinesia is not clear. We report a case of tardive dyskinesia of the perioral area and the tongue after long-term use of zuclopenthixol decanoate, a LAI antipsychotic is a potent dopamine (D2) receptor antagonist. The patient was a 45-year-old Caucasian male with a 25-year history of schizophrenia who was using olanzapine and zuclopenthixol decanoate at the index consultation when the dyskinesia was recognized. Chlorpromazine, haloperidol, olanzapine, and quetiapine were the antipsychotics that had been used for differing periods in addition to zuclopenthixol decanoate over the last six months, before the emergence of tardive dyskinesia. The Abnormal Involuntary Movements Scale was used in scoring the oropharyngeal dyskinesia. Because of the patient’s former non-compliance with oral medication and concerns of treatment adherence, we planned to continue using LAI. After switching to paliperidone palmitate, a second generation LAI with receptor-antagonist effects for dopamine (D2), serotonin (5HT-2), and noradrenaline (NE-alpha2) receptors, we observed the improvement of the tardive dyskinesia

___

  • 1. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: Therapeutic options for an increasingly common disorder. Neurothreapeutics 2014; 11:166-176. [CrossRef]
  • 2. Owens DGC. Tardive dyskinesia. A guide to the extrapyramidal side effects of antipsychotic drugs. Cambridge: Cambridge University Press, 1999; 166-226. [CrossRef]
  • 3. Nalbant A, Can A, Burhan HS, Cansiz A, Yavuz KF, Delice MA, Kurt E. Tardive dyskinesia in long term hospitalized patients with schizophrenia. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2016; 29:259-265. [CrossRef]
  • 4. Correl CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21:151-156. [CrossRef]
  • 5. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014; 20(Suppl.1):113-117. [CrossRef]
  • 6. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. MedicationInduced tardive dyskinesia: a review and update. Ochsner J 2017; 17:162-174.
  • 7. Spina E, Crupi R. Safety and efficacy of paliperidone extendedrelease in acute and maintenance treatment of schizophrenia. J Cent Nerv Syst Dis 2011; 3:27-41. [CrossRef]
  • 8. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005; 162:1984-1985. [CrossRef]
  • 9. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA,Zipursky RB, Kapur S. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response- a double blind PET study in schizophrenia. Neuropsychopharmacology 2007; 32:1209-1215. [CrossRef]
  • 10. Gopal S, Vijapaurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52 week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2011; 25:685-697. [CrossRef]
  • 11. Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long term study. Schizophr Res 2005; 77:129-139. [CrossRef]
  • 12. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2010; 30:531-540. [CrossRef]
  • 13. Gopal S, Xu H, Bossie C, Buron JA, Fu DJ, Savitz A, Nuamah I, Hough D. Incidence of tardive dyskinesia: a comparison of longacting injectable and oral paliperidone clinical trial databases. Int J Clin Pract 2014; 68:1514-1522. [CrossRef]
  • 14. Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev 2006; CD001164.
  • 15. Shajahan P, Spence E, Taylor M, Daniel D, Pelosi A. Comparison of the effectiveness of depot antipsychotics in routine clinical practice. Psychiatrist 2010; 34:273-279. [CrossRef]
  • 16. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20:131-137. [CrossRef]
  • 17. Kang NR, Kim MD. Tardive dyskinesia: treatment with aripiprazole. Clin Psychopharmacol Neurosci 2011; 9:1-8. [CrossRef]
  • 18. Lai CH. Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report. J Neuropsychiatry Clin Neurosci 2011; 23:E18. [CrossRef]
  • 19. Tomruk NB, Saatcioglu O, Yildizhan E, Alpay N. Aripiprazoleinduced tardive dyskinesia treated with quetiapine: a case report. Acta Neuropsychiatr 2011; 23:188-190. [CrossRef]
  • 20. Bella VL, Piccoli F. Olanzapine-induced tardive dyskinesia. Br J Psychiatry 2003; 182:81-82. [CrossRef]
  • 21. Yeh IN, Lin SK, Tsai CJ, Liu HC. Rapid onset of dyskinesia induced by olanzapine. Psychiatry Clin Neurosci 2003; 57:605- 606. [CrossRef]
  • 22. Ugurlu GK, Tufan E, Bilici R, Ugurlu M, Saglam S. Olanzapine induced tardive dyskinesia treated successfully with quetiapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:276-277. [CrossRef]
  • 23. Zincir S, Bilgen AE, Erdem M, Gunay H, Bozkurt A. A case of tardive dyskinesia due to olanzapine treatment. Bulletin of Clinical Psychopharmacology 2012; 22:268-270. [CrossRef]
  • 24. Kinon Bj, Kollack-Walker S, Jeste D, Gupta S, Chen L, Case M, Chen J, Stauffer V. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol 2015; 28:67-79. [CrossRef]
  • 25. Lally J, Byme F, Walsh E. A case of paliperidone-palmitateinduced tardive dyskinesia. Gen Hosp Psychiatry 2013; 35:213. e5-213.e7. [CrossRef]
  • 26. Boyanapally PK, Vemana N, Mulakaluri PP. A case of tardive dyskinesia with paliperidone palmitate. IP Telangana Journal of Psychiatry 2015; 1:55-57.
  • 27. Korkmaz S, Gundogan B. Tardive dyskinesia associated with paliperidone palmitate. Journal of Mood Disorders 2016; 6:41- 42. [CrossRef]
  • 28. Ma CH, Vhien YL, Liu CC, Chen IM, Lin CH. A case of tardive dystonia associated with long-acting injectable paliperidone palmitate. Eur Neuropsychopharmacol 2016; 26:1251-1252. [CrossRef]
  • 29. Jang S, Woo J. Five month persistent extrapyramidal symptoms following a single injection of paliperidone palmitate: a case report. Clin Psychopharmacol Neurosci 2017; 15:288-291. [CrossRef]
  • 30. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Longacting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013; 74:957-965. [CrossRef]
  • 31. Patel MX, Arista IA, Taylor M, Barnes TR. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res 2013; 149:141-148. [CrossRef]
  • 32. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487. [CrossRef]
Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi-Cover
  • ISSN: 1018-8681
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1984
  • Yayıncı: Kare Yayıncılık
Sayıdaki Diğer Makaleler

Relationship of Functionality with Impulsivity and Coping Strategies in Bipolar Disorder

Zuhal Koc APAYDİN, Murat İlhan ATAGÜN

Effects of Methylphenidate Treatment on Quality of Life in Adolescents

Fevziye TOROS, Ayşegül Yolga TAHİROĞLU, ÖZGE METİN, Canan Kuygun KARCİ

Is It Possible to Decrease the Burnout Level of Hospital Office Staff by Communication Skills Training Using Therapy Techniques?

Özen Önen SERTÖZ, Gulsum Berna GOKENGİN, Hadi SAGİN, OKAN GÜLBAHAR, MELTEM ÇİÇEKLİOĞLU, ÖZLEM SÜREL KARABİLGİN ÖZTÜRKÇÜ

Assessment of Perceived Parental Acceptance- Rejection and Psychological Adjustment Levels of Children Diagnosed with Attention-Deficit Hyperactivity Disorder

ESRA GÜNEY, Gülser Şenses DİNÇ, HALİME ŞENAY GÜZEL

A Little Known Topic Misophonia: Two Case Reports

Çiçek HOCAOĞLU

Asperger sendromlu ergende sınırlı ilgi örüntüsünün pedofili davranışından ayırt edilmesi: Bir olgu sunumu

Armagan ARAL, Gökçe Nur SAY, Mirac Baris USTA

Creutzfeldt-Jacob Disease with Presence of Psychomotor Agitation

Yasin Hasan BALCIOĞLU, Mucahid ERDOGAN, Cengiz DAYAN, Hayrunisa Dilek ATAKLİ

Erciyes Üniversitesi öğrencilerinde İnternet bağımlılığı ve depresyon düzeyleri

Osman GÜNAY, Ahmet ÖZTÜRK, Ebru Ergun ARSLANTAS, NERGİZ SEVİNÇ

Alexithymia, Anger and Anger Expression Styles as Predictors of Psychological Symptoms

Bukre KAHRAMANOL, İhsan DAĞ

Çocuklukta Onaylamayan Çevre Ölçeği (ÇOÇÖ) Türkçe Formu’nun geçerlik ve güvenirlik çalışması

EMRE HAN ALPAY, Zümrüt BELLUR, Arzu AYDIN